Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis

L A Cooker1, P Luneburg, C J Holmes

  • 1Baxter Healthcare Corporation, Renal Division, McGaw Park, Illinois, USA. laurie_cooker@baxter.com

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|March 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small surface pretilt strikingly affects the director profile during Poiseuille flow of a nematic liquid crystal.

Physical review letters·2010
Same author

Difficulties implementing the guidelines for the management of severe local anaesthetic toxicity.

Anaesthesia·2009
Same author

Peritoneal adhesions.

The British journal of surgery·2008
Same author

Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients.

Clinical nephrology·2005
Same author

Effectiveness of various chemical disinfectants versus cleaning combined with heat disinfection on Pseudomonas biofilm in hemodialysis machines.

Blood purification·2004
Same author

Neutrophil activity in total knee replacement: implications in preventing post-arthroplasty infection.

The Knee·2003
Same journal

Quercetin attenuates peritoneal fibrosis by upregulating ferroptosis-related glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) in MeT-5A and rat models: Supported by clinical mRNA expression data.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

An in vitro comparison of bacterial touch contamination prevention between a novel APD cycler connector and existing APD connectors.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

What is the effect of the assistance on the risk of transfer to HD after an unplanned peritoneal dialysis initiation? A cohort study with data from the RDPLF.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

2026 ISPD Position Statement on tracking and reporting loss from PD therapy.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Important factors in the choice of dialysis modality among Japanese patients initiating peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Severe hyponatremia associated with unintended infusion of an unmixed neutral-pH peritoneal dialysis solution in an elderly patient with cognitive impairment.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
See all related articles

A new bicarbonate/lactate peritoneal dialysis (PD) solution reduced inflammation markers interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). This suggests improved biocompatibility and potential for preserving PD membrane function.

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Inflammation Research

Background:

  • Conventional lactate-buffered peritoneal dialysis (PD) solutions exhibit bioincompatible properties like acidic pH and glucose degradation products (GDPs).
  • These factors, alongside inflammation, are implicated in the progression of peritoneal membrane dysfunction among PD patients.
  • A novel bicarbonate/lactate buffered PD solution with physiological pH and reduced GDPs has demonstrated enhanced biocompatibility in preliminary studies.

Purpose of the Study:

  • To evaluate the impact of a new bicarbonate/lactate (B/L) buffered PD solution on intraperitoneal inflammatory markers.
  • To compare the concentrations of interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in PD effluents between B/L and conventional lactate-based solutions.

Main Methods:

Related Experiment Videos

  • A randomized controlled trial involving 92 continuous ambulatory peritoneal dialysis (CAPD) patients.
  • Patients were assigned to receive either a control lactate-based solution (C) or the new bicarbonate/lactate (B/L) solution for 6 months.
  • Overnight PD effluents were collected at baseline, 3 months, and 6 months, and analyzed for IL-6, TNFalpha, and VEGF using ELISA.

Main Results:

  • The B/L solution group showed a significant reduction in effluent IL-6 levels at both 3 and 6 months.
  • A significant decrease in VEGF levels was observed at 3 months in the B/L group.
  • No significant changes in IL-6 or VEGF were noted in the control group, and TNFalpha levels remained unchanged in both groups.

Conclusions:

  • Treatment with the bicarbonate/lactate (B/L) PD solution is associated with reduced IL-6 synthesis and VEGF secretion.
  • These findings suggest that the B/L solution mitigates intraperitoneal inflammation and may reduce the potential for angiogenesis.
  • The use of B/L solution holds promise for restoring peritoneal homeostasis and preserving long-term peritoneal membrane function in PD patients.